pulmonary embolism
Study compares dabigatran to warfarin in treating blood clots
- Fri, 06/08/2012 - 12:31pm
A study headed by Boehringer Ingelheim, the maker of Pradaxa, suggests a fixed dose of dabigatran therapy twice daily
Pradaxa ranks first among drugs most often reported to the FDA
- Thu, 06/07/2012 - 10:27am
The Institute for Safe Medication Practices listed Pradaxa (dabigatran) as the drug most commonly reported to the U.S.
Government agency cautions against hormone replacement therapy
- Thu, 05/31/2012 - 1:40pm
In 2009, the U.S.
Study compares dabigatran to warfarin in VTE treatment
- Tue, 05/29/2012 - 11:06am
A study conducted primarily by Boehringer Ingelheim, the maker of Pradaxa, suggests a fixed dose of dabigatran therapy